Results 101 to 110 of about 740 (167)

P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP

HemaSphere, 2022
U. Platzbecker, E. Angelucci, P. Montesinos, R. M. Lemoli, A. Spyridonidis, J. Casariego, T. I. Mughal, M. Mohty   +7 more
doaj   +1 more source

P530: TAGRAXOFUSP IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH/WITHOUT CENTRAL NERVOUS SYSTEM INVOLVEMENT AND INTRATHECAL CHEMOTHERAPY AS PRIMARY TREATMENT OR PROPHYLAXIS: AN ITALIAN EXPERIENCE.

HemaSphere, 2022
G. Rivoli, G. Beltrami, A. Raiola, A. Dominietto, M. Riggi, E. Angelucci   +5 more
doaj   +1 more source

PB1902: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF TAGRAXOFUSP, A CD123-DIRECTED THERAPY, FOR THE TREATMENT OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

HemaSphere, 2023
Uwe Platzbecker, Emanuele Angelucci, Pau Montesinos, Roberto M. Lemoni, Alexandros Spyridonidis, Marcello Riggi, Michael Zuurman, Mohamad Mohty   +7 more
doaj   +1 more source

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. [PDF]

Leukemia
Beird HC, Kannan S, Liu J, Chen J, Olguin A, Desai P, Cai T, Han L, Cotton JL, Singh S, Gupta SK, Little L, Estecio MR, Song X, Abbas HA, Zhang J, Gumbs C, Brooks C, Kantarjian H, Andreeff M, Konopleva M, Futreal PA, Pemmaraju N.   +22 more
europepmc   +1 more source

Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Int J Dermatol
Gandarillas S, Mehregan D, Wolfe S, Dasgeb B.   +3 more
europepmc   +1 more source

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. [PDF]

Blood Neoplasia
Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N.   +11 more
europepmc   +1 more source

Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Acta Haematol
Ambinder A, LeBlanc TW, Levy MY, Patel AB, McCloskey J, Duffield E, Katsetos J, Mannis G.   +7 more
europepmc   +1 more source

Relapsing Blastic Plasmacytoid Dendritic Cell Neoplasm With Neurologic Involvement. [PDF]

Cureus
Rahman Z, Haley A, Gandhi S, Mohamed A, Parza K, Quan JR.   +5 more
europepmc   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review of Literature. [PDF]

Cureus
Staessens S, De Beule N, Trullemans F, De Becker A.   +3 more
europepmc   +1 more source

Correction to "Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm". [PDF]

Cancer
europepmc   +1 more source